# Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Study · id `cardio:ct-nct02160145` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02160145](<https://clinicaltrials.gov/study/NCT02160145>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02160145

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1370 participants.

## Technical summary

Registry record NCT02160145. Randomized; quadruple masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2017-04-18 (actual). Results posted on 2018-08-08.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1370 participants (enrolled count; ClinicalTrials.gov record NCT02160145, source copy `cardio:ctgov-nct02160145-2018-08-08`, retrieved 2026-10-26)
- Start date: 2014-05 (registry gives no type) (ClinicalTrials.gov record NCT02160145, source copy `cardio:ctgov-nct02160145-2018-08-08`, retrieved 2026-10-26)
- Primary completion: 2017-04-18 (actual) (ClinicalTrials.gov record NCT02160145, source copy `cardio:ctgov-nct02160145-2018-08-08`, retrieved 2026-10-26)
- Completion: 2017-04-18 (actual) (ClinicalTrials.gov record NCT02160145, source copy `cardio:ctgov-nct02160145-2018-08-08`, retrieved 2026-10-26)
- Results first posted: 2018-08-08 (ClinicalTrials.gov record NCT02160145, source copy `cardio:ctgov-nct02160145-2018-08-08`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Canada; Czechia; Denmark; France; Germany; Hungary; Israel; Italy; Netherlands; Norway; Poland; Puerto Rico; Romania; Russia; South Africa; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT02160145, source copy `cardio:ctgov-nct02160145-2018-08-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02160145-2018-08-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
- Condition: Chronic Kidney Disease
- Condition: Autosomal Dominant Polycystic Kidney Disease
- Intervention (Drug): Tolvaptan (OPC-41061)
- Intervention (Drug): Placebo
- Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. (`cardio:org-otsuka-pharmaceutical-development-commercialization-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease (`cardio:pubmed-29105594`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0ce2e540e9585a4ddc6ebb304940e3b16fea91a0381b1f275ee4aeaa1ba51980
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
